Coronavirus Patients in Limbo as Gilead Suspends Emergency Drug Access [The New York Times]
Quest Diagnostics Incorporated (DGX)
Last quest diagnostics incorporated earnings: 4/22 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
ir.questdiagnostics.com
Company Research
Source: The New York Times
Health | Coronavirus Patients in Limbo as Gilead Suspends Emergency Drug Access https://nyti.ms/2WBXDbz The Coronavirus Outbreak debugid:204 ment Continue reading the main story Supported by The company says it will switch to a broader approach for its experimental drug, remdesivir. But it was overwhelmed by demand for a potential treatment promoted by President Trump. By Katie Thomas March 23, Overwhelmed by demand for an experimental treatment for coronavirus, the drug maker Gilead abruptly shut down its emergency access program, leaving doctors and families scrambling for answers. The company said it was setting up a broader access program that could try to help more people, but some said the transition is delaying remedies for very ill patients who have few options. “We have heard zero. We know nothing,” said Genny Allard, the mother of Jack Allard, a 25-year-old New Jersey resident who is in a medically induced coma and on a ventilator at Hackensack Meridian Health JFK M
Show less
Read more
Impact Snapshot
Event Time:
DGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DGX alerts
High impacting Quest Diagnostics Incorporated news events
Weekly update
A roundup of the hottest topics
DGX
News
- $6.1 Bn Dietary Supplement Testing Services Global Market Opportunities and Strategies to 2033: Contaminant Testing Platforms, Adulteration Panel Analysis, AI-Driven Platforms for Improved Testing [Yahoo! Finance]Yahoo! Finance
- Quest Diagnostics (DGX) Up 2.7% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]Yahoo! Finance
- Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
- Quest Diagnostics Incorporated (NYSE: DGX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Vitamin D Testing Market Size to Reach USD 1774.70 Million by 2031 | SkyQuest Technology [Yahoo! Finance]Yahoo! Finance
DGX
Earnings
- 10/22/24 - Beat
DGX
Sec Filings
- 11/7/24 - Form 4
- 10/30/24 - Form 4
- 10/28/24 - Form 144
- DGX's page on the SEC website